Retatrutide is currently under investigation in a global phase 3 clinical trial programme, following promising results from its phase 2 study (NCT04881760) published in the New England Journal of Medicine in 2023
The results revealed an average 14.9% reduction in body weight from baseline during 68 weeks of treatment with semaglutide 2.4 mg plus a lifestyle intervention, compared with just a 2.4% reduction in the placebo plus lifestyle intervention group
Keep vials in their original packaging away from direct light
State and federal inspectors can then check the facilities, increasing the likelihood of consistent safety and sterility, he says
Strength training is especially important for maintaining lean muscle mass, which can help boost your metabolism and burn more calories at rest
Thus, GLP-1RAs could be recommended as an alternative treatment for various metabolic diseases that cause visceral fat accumulation [70]